Pay in 4 interest-free payments of $6.79 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Kulak MV, Cyr AR, Woodfield GW, Bogachek M, Spanheimer PM, Li T, Price DH, Domann FE, Weigel RJ
According to a clinical research plan updated by the company in early 2024, Lilly will conduct multiple Phase 3 clinical trials for Retatrutide over the next three years, with targeted indications primarily including obesity, chronic kidney disease, and type 2 diabetes
Lack of Secure Logistics : Retatrutide is a fragile peptide that requires careful handling
Patients transitioning from any other compounded GLP-1 platform should document their current medication, current weekly dose, duration at that dose, and clinical response in the Direct Meds intake questionnaire
US$ 23.43
US$ 27.13
US$ 20.59
US$ 20.06
US$ 27.31
US$ 27.49
US$ 28.99
